Clinical Trial Disruptions: Can Small-Cap Biopharma Companies Weather the Impact of COVID-19?

Can small biopharma companies overcome the impact of COVID-19

Executive Summary Ongoing clinical trial disruptions due to COVID-19, such as: operational delays, enrollment challenges, protocol adjustments, and decreased short- / moderate-term persistence, contribute to the uncertain outlook for industry research programs Small-cap, clinical-stage biopharma companies lacking a cashflow from marketed products stand to be particularly affected by COVID-19. A…